



**EXTERNALLY-LED
PATIENT-FOCUSED DRUG DEVELOPMENT MEETING
FOR SCN2A-RELATED DISORDERS**

**Friday, October 23, 2026
10 am - 3:15 pm ET**

Registration and Breakfast (9:00 am - 10:00 am)

Meeting Opening (10:00 am – 10:30 am)

- Welcome (5 min) - Leah Schust Myers (Executive Director)
- Opening Remarks (5 min) - Dr. Michelle Campbell (FDA)
- Clinical Overview (10 min) - Dr. Laura McGarry (Clinician Researcher)
- Overview of Discussion Format (5 min) - Dr. Kevin Bender (Moderator)
- Audience Polling (5 min) - Dr. Christina SanInocencio (Moderator)

Topic 1: Health Effects and Daily Impacts (10:30 am - 12:00 pm)

- Panel of patients / caregivers provide comments to start the discussion (25 mins)
- Large-Group Facilitated Discussion on Topic 1 (65 min)
 - Patients / caregivers in the audience are invited to add to the dialogue

Lunch Break & Group Photo (12:00 pm - 1:00 pm)

Topic 2: Current Approaches to Treatment (1:00 pm - 2:00 pm)

- Panel (20 min)
 - A panel of patients / caregivers will provide comments to start the discussion
- Large-Group Facilitated Discussion on Topic 2 (40 min)
 - Patients / caregivers in the audience are invited to add to the dialogue

Break (2:00 pm - 2:15 pm)

Topic 3: Patient Perspectives on Clinical Trials (2:15 pm - 3:10 pm)

- Panel (15 min)
 - A panel of patients / caregivers will provide comments to start the discussion
- Large-Group Facilitated Discussion on Topic 2 (40 min)
 - Patients / caregivers in the audience are invited to add to the dialogue.

Closing Remarks & Next Steps (3:10 - 3:15 pm)

Reception in lobby